Susquehanna International Group
CRBP icon

Susquehanna International Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Susquehanna International Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$675K Buy
+71,900
New +$605K ﹤0.01% 8888
2025
Q4 		– Sell
-194,900
Closed -$2.47M – 12518
2025
Q3 		$2.47M Buy
+194,900
New +$1.85M ﹤0.01% 5345
2025
Q1 		– Sell
-49,000
Closed -$578K – 12594
2024
Q4 		$578K Sell
49,000
-58,600
-54% -$983K ﹤0.01% 8308
2024
Q3 		$2.22M Buy
107,600
+89,100
+482% +$4.56M ﹤0.01% 5063
2024
Q2 		$837K Sell
18,500
-30,600
-62% -$1.29M ﹤0.01% 7007
2024
Q1 		$1.93M Buy
49,100
+13,800
+39% +$340K ﹤0.01% 5428
2023
Q4 		$213K Hold
35,300
– – ﹤0.01% 10554
2023
Q3 		$238K Sell
35,300
-200
-0.6% -$1.38K ﹤0.01% 9843
2023
Q2 		$278K Hold
35,500
– – ﹤0.01% 9597
2023
Q1 		$258K Buy
35,500
+33,797
+1,985% +$148K ﹤0.01% 10053
2022
Q4 		$5.62K Sell
1,703
-1,880
-52% -$7.23K ﹤0.01% 12025
2022
Q3 		$18K Sell
3,583
-1,400
-28% -$9.87K ﹤0.01% 12628
2022
Q2 		$37K Buy
4,983
+1,090
+28% +$10.5K ﹤0.01% 12127
2022
Q1 		$62K Buy
3,893
+2,710
+229% +$35.9K ﹤0.01% 12206
2021
Q4 		$22K Sell
1,183
-4,394
-79% -$119K ﹤0.01% 12809
2021
Q3 		$171K Sell
5,577
-3,686
-40% -$145K ﹤0.01% 11655
2021
Q2 		$509K Sell
9,263
-1,000
-10% -$55.5K ﹤0.01% 9549
2021
Q1 		$607K Buy
10,263
+2,800
+38% +$184K ﹤0.01% 9030
2020
Q4 		$280K Sell
7,463
-36,244
-83% -$1.36M ﹤0.01% 9400
2020
Q3 		$2.36M Buy
43,707
+14,954
+52% +$2.71M ﹤0.01% 4305
2020
Q2 		$7.24M Buy
28,753
+13,416
+87% +$2.71M ﹤0.01% 2532
2020
Q1 		$2.41M Buy
15,337
+14,760
+2,558% +$2.5M ﹤0.01% 3643
2019
Q4 		$94K Sell
577
-3,100
-84% -$458K ﹤0.01% 9163
2019
Q3 		$537K Sell
3,677
-460
-11% -$80.1K ﹤0.01% 7137
2019
Q2 		$860K Sell
4,137
-5,370
-56% -$1.15M ﹤0.01% 6026
2019
Q1 		$1.98M Buy
9,507
+8,184
+619% +$1.8M ﹤0.01% 3759
2018
Q4 		$232K Sell
1,323
-4,897
-79% -$977K ﹤0.01% 7468
2018
Q3 		$1.41M Buy
6,220
+4,847
+353% +$784K ﹤0.01% 4598
2018
Q2 		$208K Buy
+1,373
New +$249K ﹤0.01% 8539
2017
Q4 		– Sell
-983
Closed -$211K – 9311
2017
Q3 		$211K Buy
983
+600
+157% +$117K ﹤0.01% 7933
2017
Q2 		$72K Sell
383
-4,604
-92% -$903K ﹤0.01% 8808
2017
Q1 		$1.23M Buy
4,987
+857
+21% +$210K ﹤0.01% 4696
2016
Q4 		$1.05M Buy
4,130
+3,277
+384% +$751K ﹤0.01% 5443
2016
Q3 		$174K Buy
+853
New +$106K ﹤0.01% 7682

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's CRBP Position: Q1 2026 in Review

Susquehanna International Group increased its Corbus Pharmaceuticals (CRBP) stake by 46% in Q1 2026, buying an estimated $889K and bringing the position to 333,415 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5188.

Susquehanna International Group first reported a position in CRBP in Q3 2016 and has held it in 32 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Susquehanna International Group held 333,415 shares of Corbus Pharmaceuticals worth $3.13M as of Q1 2026.
  • Susquehanna International Group bought 105,589 Corbus Pharmaceuticals shares in Q1 2026, an estimated $889K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5188 holding.
  • Susquehanna International Group first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 32 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.